Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximate… Read More
Targeted protein degradation (TPD) technology has been developed rapidly in recent years, especially proteolysis targeting chimeras (PROTACs). To date, a large number of degraders have been… Read More
Abstract
Identifying mutations in the KRAS gene has become increasingly important in the treatment of colorectal cancer with many prognostic and therapeutic implications. Howeve… Read More
KRAS is a common type of oncogene and is involved in at least one-fifth of all human cancers. KRAS mutations cause 32% of lung tumors and 96% of pancreatic tumors. However, after more than 3… Read More
With the increasingly fierce competition in the field of oncology drug R&D, the exploration of various drug forms based on established drug targets is a relatively low-risk R&D optio… Read More
Liver cancer is the fifth most common cancer in the world and the second leading cause of cancer death. Cholangiocarcinoma is the second most common liver cancer. It is a malignant… Read More
An Introduction
As one of the leading causes of cancer death in many industrialized countries, Lung Cancer (LC) claims more than 160,000 and 50,000 lives annually in the America… Read More
When signaling pathways within cells are triggered, proteins activate by a sequence reaction, like a quarrel of acrobatics dominoes, until a final protein influences some mobile function. In… Read More
For some-more than 3 decades, scientists have tried, with small success, to aim a mutant KRAS oncogene with drugs. So instead, some researchers have attempted to aim associated biological pa… Read More
In a recent study published in the journal Cancer Cell, researchers from Columbia University Medical Center found that stress may accelerate the development of pancreatic cancer by stimulati… Read More